Peginterferon alfa-2b

Identification

Name
Peginterferon alfa-2b
Accession Number
DB00022 / G8RGG88B68
Groups
Pegetron
Description

Peginterferon alfa-2b is a shape of recombinant interferon used as part of combination therapy to treat continual Hepatitis C, an infectious liver disease resulting from infection with Hepatitis C Virus (HCV). HCV is a unmarried-stranded RNA virus this is categorised into 9 distinct genotypes, with genotype 1 being the most common within the america, and affecting seventy two% of all persistent HCV patients [L852]. treatment options for continual Hepatitis C have superior drastically on account that 2011, with the improvement of Direct appearing Antivirals (DAAs) ensuing in much less use of Peginterferon alfa-2b. Peginterferon alfa-2b is derived from the alfa-2b moeity of recombinant human interferon and acts with the aid of binding to human type 1 interferon receptors. Activation and dimerization of this receptor induces the body's innate antiviral reaction by using activating the janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway. Use of Peginterferon alfa-2b is related to a huge range of excessive unfavourable consequences together with the aggravation and development of endocrine and autoimmune issues, retinopathies, cardiovascular and neuropsychiatric complications, and elevated risk of hepatic decompensation in sufferers with cirrhosis. the use of Peginterferon alfa-2b has in large part declined seeing that more recent interferon-free antiviral treatment plans have been developed. In a joint advice posted in 2016, the yank association for the look at of Liver diseases (AASLD) and the Infectious sicknesses Society of the usa (IDSA) no longer endorse Peginterferon alfa-2b for the remedy of Hepatitis C [A19593]. Peginterferon alfa-2b turned into used alongside [DB00811] with the motive to treatment, or obtain a sustained virologic response (SVR), after 48 weeks of remedy. SVR and eradication of HCV infection is associated with widespread lengthy-time period health advantages including decreased liver-associated damage, progressed excellent of lifestyles, decreased prevalence of Hepatocellular Carcinoma, and decreased all-purpose mortality [A19626]. Peginterferon alfa-2b is to be had as a variable dose injectable product (tradename Pegintron) used for the remedy of continual Hepatitis C. authorized in 2001 by using the FDA, Pegintron is indicated for the remedy of HCV with [Ribavirin] or other antiviral capsules [FDA Label]. whilst blended collectively, Peginterferon alfa-2b and [Ribavirin] had been proven to achieve a SVR among 41% for genotype 1 and seventy five% for genotypes 2-6 after forty eight weeks of treatment.

Pharmacology

Pharmacodynamics

Peginterferon alfa-2b inhibits viral replication in infected cells, suppresses cell proliferation, induces apoptosis, and exerts an anti-angiogenic effect [FDA Label]. Exerts immunomodulatory effects such as enhancement of the phagocytic activity of macrophages, activation of NK cells, stimulation of cytotoxic T-lymphocytes, and the upregulation of the Th1 T-helper cell subset. Also increases concentrations of effector proteins such as serum neopterin and 2'5' oligoadenylate synthetase, raises body temperature, and causes reversible decreases in leukocyte and platelet counts.

Indication

Peginterferon alfa-2b is indicated for the treatment of HCV in combination with [DB00811] and a NS3/4A protease inhibitor for genotype 1 or without a NS3/4A protease inhibitor for genotypes 2-6 [FDA Label]. May be used as a monotherapy in patients with contraindications to or significant intolerance to other anti-viral therapies.

Action

Peginterferon alfa-2b is derived from recombinant human interferon's alfa-2b moeity [FDA Label]. It binds to and activates human type 1 interferon receptors causing them to dimerize. This activates the JAK/STAT pathway. Activation of the JAK/STAT pathway increases expression of multiple genes in multiple tissues involved in the innate antiviral response. Peginterferon alfa-2b may also acitvate the nuclear factor κB pathway.